446 related articles for article (PubMed ID: 3510720)
21. Immunological and pharmacological removal of small cell lung cancer cells from bone marrow autografts.
Humblet Y; Feyens AM; Sekhavat M; Agaliotis D; Canon JL; Symann ML
Cancer Res; 1989 Sep; 49(18):5058-61. PubMed ID: 2548708
[TBL] [Abstract][Full Text] [Related]
22. Elimination of malignant clonogenic cells from human bone marrow using multiple myeloid cell-specific monoclonal antibodies and complement.
Hu ZB; Yu ZF; Qiao CN; Ma WL
Chin Med J (Engl); 1991 Aug; 104(8):664-8. PubMed ID: 1914634
[TBL] [Abstract][Full Text] [Related]
23. Properties of immunotoxins against a glycolipid antigen associated with Burkitt's lymphoma.
Wiels J; Junqua S; Dujardin P; Le Pecq JB; Tursz T
Cancer Res; 1984 Jan; 44(1):129-33. PubMed ID: 6690030
[TBL] [Abstract][Full Text] [Related]
24. Serological study for in vitro use of monoclonal antibody for autologous bone marrow transplantation in null cell-type acute lymphocytic leukemia.
Sao H; Morishima Y; Ueda R; Yoshikawa S; Kodera Y; Ohno R; Takahashi T
Jpn J Cancer Res; 1985 Dec; 76(12):1212-21. PubMed ID: 3937833
[TBL] [Abstract][Full Text] [Related]
25. Antitumor activity of L6-ricin immunotoxin against the H2981-T3 lung adenocarcinoma cell line in vitro and in vivo.
Schmidberger H; King L; Lasky LC; Vallera DA
Cancer Res; 1990 Jun; 50(11):3249-56. PubMed ID: 1692258
[TBL] [Abstract][Full Text] [Related]
26. Mouse L1210V leukemia as a model to analyse efficiency of leukemic cell elimination by immunotoxin, antibody and complement, and cytostatic agents.
Paprocka M; Wiedlocha A; Radzikowski C
In Vivo; 1990; 4(3):209-13. PubMed ID: 2133264
[TBL] [Abstract][Full Text] [Related]
27. Specific killing of human T-leukemia cells by immunotoxins prepared with ricin A chain and monoclonal anti-human T-cell leukemia antibodies.
Seon BK
Cancer Res; 1984 Jan; 44(1):259-64. PubMed ID: 6606488
[TBL] [Abstract][Full Text] [Related]
28. Monoclonal antibody SN10 which shows a highly selective reactivity with human B leukemia-lymphoma and is effectively internalized into cells.
Takeuchi T; Barcos MP; Seon BK
Cancer Res; 1991 Jun; 51(11):2985-93. PubMed ID: 1709587
[TBL] [Abstract][Full Text] [Related]
29. Specific ex-vivo depletion of human bone marrow T lymphocytes by an anti-pan-T cell (CD5) ricin A-chain immunotoxin.
Siena S; Villa S; Bonadonna G; Bregni M; Gianni AM
Transplantation; 1987 Mar; 43(3):421-6. PubMed ID: 3103275
[TBL] [Abstract][Full Text] [Related]
30. In vitro cytotoxicity of VP-16-213 and nitrogen mustard: agonistic on tumor cells but not on normal human bone marrow progenitors.
Lemoli RM; Gulati SC
Exp Hematol; 1990 Oct; 18(9):1008-12. PubMed ID: 2397748
[TBL] [Abstract][Full Text] [Related]
31. Preclinical evaluation of immunoconjugates consisting of doxorubicin linked to complement-fixing monoclonal antibody DLC-48 for bone marrow purging of B-cell lymphomas.
Winter JN; Bass B; Bringman T; Nedwin G
Prog Clin Biol Res; 1990; 333():171-83. PubMed ID: 2408059
[TBL] [Abstract][Full Text] [Related]
32. Elimination of chemoresistant myeloma clonogenic cells from human bone marrow by monoclonal antibody and complement.
Tong AW; Dalton WS; Tsuruo T; Fay JW; Stone MJ
Prog Clin Biol Res; 1990; 333():155-64. PubMed ID: 2308979
[TBL] [Abstract][Full Text] [Related]
33. Cytotoxic effect of anti-Mr 67,000 protein immunotoxins on human tumors in a nude mouse model.
Weil-Hillman G; Runge W; Jansen FK; Vallera DA
Cancer Res; 1985 Mar; 45(3):1328-36. PubMed ID: 3971376
[TBL] [Abstract][Full Text] [Related]
34. Elimination of chemoresistant multiple myeloma clonogenic colony-forming cells by combined treatment with a plasma cell-reactive monoclonal antibody and a P-glycoprotein-reactive monoclonal antibody.
Tong AW; Lee J; Wang RM; Dalton WS; Tsuruo T; Fay JW; Stone MJ
Cancer Res; 1989 Sep; 49(17):4829-34. PubMed ID: 2569359
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of a combined treatment with ASTA-Z 7654 and VP16-213 in vitro in eradicating clonogenic tumor cells from human bone marrow.
De Fabritiis P; Pulsoni A; Sandrelli A; Simone F; Amadori S; Meloni G; Mandelli F
Bone Marrow Transplant; 1987 Oct; 2(3):287-98. PubMed ID: 3502785
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of monoclonal antibody DF3 conjugated with ricin as a specific immunotoxin for in vitro purging of human bone marrow.
Tondini C; Pap SA; Hayes DF; Elias AD; Kufe DW
Cancer Res; 1990 Feb; 50(4):1170-5. PubMed ID: 2404589
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of an anti-CD7-ricin A chain immunoconjugate in a novel murine model of human T-cell leukemia.
Fishwild DM; Aberle S; Bernhard SL; Kung AH
Cancer Res; 1992 Jun; 52(11):3056-62. PubMed ID: 1375534
[TBL] [Abstract][Full Text] [Related]
38. Preliminary clinical trial of autologous bone marrow transplantation after in vitro monoclonal antibody and complement treatments in null cell-type acute lymphocytic leukemia.
Morishima Y; Sao H; Ueda R; Morishita Y; Murase T; Kodera Y; Ohno R; Tahara T; Yoshikawa S; Kato Y
Jpn J Cancer Res; 1985 Dec; 76(12):1222-9. PubMed ID: 3937834
[TBL] [Abstract][Full Text] [Related]
39. Complement depletion in vitro limits monoclonal antibody 6-19-dependent complement-mediated killing of tumor cells in bone marrow.
Duerst RE; Rose D; Frantz CN
Exp Hematol; 1991 Oct; 19(9):863-7. PubMed ID: 1893961
[TBL] [Abstract][Full Text] [Related]
40. Anti-T cell immunotoxins containing pokeweed anti-viral protein: potential purging agents for human autologous bone marrow transplantation.
Ramakrishnan S; Uckun FM; Houston LL
J Immunol; 1985 Nov; 135(5):3616-22. PubMed ID: 3900212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
